Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Group 1 - Coya Therapeutics (NASDAQ: COYA) experienced a significant setback in 2024 due to the release of data from its phase 2 study on Low-Dose IL-2 COYA-301 for Alzheimer's Disease treatment [2] - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central service, providing in-depth analysis of various pharmaceutical companies [2] Group 2 - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks, offering detailed analysis for each [2]